Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens-Reference-Cited by-同舟云学术

Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens

Published:2023-05-17 Issue:5 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Zhu Yue¹,Zhu Limei²^ORCID,Davies Forsman Lina³⁴^ORCID,Paues Jakob⁵⁶,Werngren Jim⁷,Niward Katarina⁵⁶,Schön Thomas⁵⁶⁸,Bruchfeld Judith³⁴,Xiong Haiyan¹,Alffenaar Jan-Willem⁹¹⁰¹¹^ORCID,Hu Yi¹^ORCID

Affiliation:

1. Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China

2. Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China

3. Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden

4. Department of Medicine, Division of Infectious Diseases, Karolinska Institutet, Solna, Stockholm, Sweden

5. Department of Biomedical and Clinical Sciences, Linköping, University, Linköping, Sweden

6. Department of Infectious Diseases, Linköping University Hospital, Linköping, Sweden

7. Department of Microbiology, Public Health Agency of Sweden, Stockholm, Sweden

8. Department of Infectious Diseases, Kalmar County Hospital, Kalmar, Linköping University, Sweden

9. Faculty of Medicine and Health, School of Pharmacy, University of Sydney, Sydney, Australia

10. Westmead Hospital, Sydney, Australia

11. Sydney Institute for Infectious Diseases, University of Sydney, Sydney, Australia

Abstract

Although cycloserine is a recommended drug for the treatment of multidrug-resistant tuberculosis (MDR-TB) according to World Health Organization (WHO), few studies have reported on pharmacokinetics (PK) and/or pharmacodynamics (PD) data of cycloserine in patients with standardized MDR-TB treatment. This study aimed to estimate the population PK parameters for cycloserine and to identify clinically relevant PK/PD thresholds, as well as to evaluate the current recommended dosage.

Funder

National Natural Science Foundation of China

Swedish Research Council

Swedish Heart and Lung Foundation

County of Stockholm

Research Council of south-eastern Sweden

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01700-22

Reference29 articles.

1. WHO. 2019. WHO consolidated guidelines on drug-resistant tuberculosis treatment. https://www.ncbi.nlm.nih.gov/books/NBK539517/. Accessed 1 December 2022.

2. Comparative fitness analysis of D-cycloserine resistant mutants reveals both fitness-neutral and high-fitness cost genotypes

3. d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal

4. WHO. 2018. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. https://www.who.int/publications/i/item/WHO-CDS-TB-2018.5. Accessed 1 December 2022.

5. Population pharmacokinetics of moxifloxacin, cycloserine, p -aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and Safety of Group A and B Anti-Tuberculosis Drugs Used in Treatment of Rifampicin-Resistant Tuberculosis during Pregnancy and Post-Partum: A Narrative Review;Pathogens;2023-11-24